FDA, CMS Have Common Mission Of Promoting Access To Innovative Drugs, McClellan Says
This article was originally published in The Pink Sheet Daily
CMS is a "public health agency very much like FDA," Commissioner McClellan says in address to Medicare Congress. New role as CMS administrator will include some carryover responsibilities, McClellan indicates.
You may also be interested in...
New biologic for severe asthma doesn't stack up well to standard of care on generally accepted levels of cost per quality-adjusted life year.
Busy week for AstraZeneca sees buyout of Acerta and acquisition of remaining Daliresp/Daxas worldwide rights from Takeda. Amgen and GSK undo their cancer drug alliances from 2009 and 2010, with all rights reverting to the big biotech.
FDA/CMS Summit speakers say they've yet to see any real interest from manufacturers in putting money at risk if their products don't meet outcome measures.